Dolasetron

Exposed non-exposed, cohort studies

Study Country
Study period
Study design
Data source Exposure definition Non-exposure definition Exposition period Sample size
(exposed/unexposed) Or (case / control)
Remarks Overall risk of bias

Empty. There are no case-control studies available for this drug.

Case-control studies

Study Country
Study period
Study design
Data source Case Control Exposition Exposition period Sample size
(exposed/unexposed) Or (case / control)
Remarks Overall risk of bias
Fejzo
2015
USA
2007 - 2011
case control
A part of a larger investigation evaluating the 44 genetics and epidemiology of Hyperemesis gravidarum (HG) Children exposed to hyperemesis gravidarum (HG) with neurodevelopmental delay. Children exposed to hyperemesis gravidarum (HG) with a good outcome. Participants were asked to submit their medical records and complete an online survey regarding treatment. during pregnancy (anytime or not specified) 138 / 174 Main analysis: case control related to the impact of the HG illness (treated or not) on child outcomes. Then impact of 37 medications/treatments (1st and/or 2nd trimester) on child outcome was investigated (none was significantly associated with delay). critical
Participants were asked to submit their medical records and complete an online survey regarding outcomes. A follow-up survey was administered on the diagnosis of childhood emotional, behavioral, and learning disorders.
Fejzo
2013
USA
2007 - 2011
case control
A part of a larger investigation evaluating the genetics and epidemiology of Hyperemesis gravidarum (HG). Pregnant women with hyperemesis gravidarum (HG) who have negative outcomes (birth weight less than 10%, perinatal mortality, and/or preterm birth (<37 weeks)). Pregnant women with hyperemesis gravidarum (HG) who have positive outcomes. Participants were asked to submit their medical records and complete an online surveyregarding treatment. The majority of participants, both cases and controls, joined the study and began the survey during their pregnancies. during pregnancy (anytime or not specified) 43 / 211 Comparison of use of various medications/treatments in the two groups (43 HG participants with an adverse outcome compared to 211 HG participants with a good outcome). NA
Participants were asked to submit their medical records and complete an online surveyregarding outcomes. The majority of participants, both cases and controls, were automatically prompted to complete the survey on outcome following their due date.

See the method used to produce these results